Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2Urinary Bladder Neoplasms 1Medulloblastoma 1Endometrial Endometrioid Adenocarcinoma 1Breast Cancer Female 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Temozolomide 6Radiotherapy 6fluciclovine F-18 4Topotecan 4fluorodopa F 18 3Biopsy 3niraparib 2abemaciclib 2Standard of Care 2Specimen Handling 2Pemetrexed 2Ketoconazole 2ulixertinib 1temsirolimus 1ribociclib 1posaconazole 1poly ICLC 1pitavastatin 1pembrolizumab 1orludodstat 1lorlatinib 1larotrectinib 1infigratinib 1fisetin 1fimepinostat 1evolocumab 1clevudine 1X-Rays 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Glioma × abemaciclib × Clear all
NCT04391595 2026-03-06

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Completed
42 enrolled
CNS

Glioblastoma, Glioma

NCT04220892 2020-07-31

Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

Saint John's Cancer Institute

Phase EARLY_PHASE1 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡